Questions discussed in this category
There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?
Please specify how your institution is allocating resources now or will be soon.
Would you have reservations in treating patients with breast, GI, or pelvic malignancies with radiation alone or concurrent chemoradiation?
If proton therapy is not available would you consider radiosurgery?
How would your management differ if residual disease is present?
How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...
-The data on induction for adult H&N ca has been mixed (excluded NPX) but recent data suggest a benefit for adult NPX.
-Given that this is standa...
Would the risk of secondary malignancy affect the decision?
20370165681638073817875671861652357
Papers discussed in this category
J. Clin. Oncol., 2019 Sep 25
AJNR. American journal of neuroradiology, 1996-02
International journal of radiation oncology, biology, physics, 2009-11-15
International journal of radiation oncology, biology, physics, 2011-11-15
International journal of radiation oncology, biology, physics, 2012-08-01
International journal of radiation oncology, biology, physics, 2013-07-01
Int J Radiat Oncol Biol Phys, 2008 May 1
Int J Radiat Oncol Biol Phys, 2007 Feb 1
Int J Radiat Oncol Biol Phys, 2005 Oct 1
Ann. Oncol.,
Journal of the National Cancer Institute, 2016-06
Pediatrics, 2014 Feb 02
N. Engl. J. Med.,
The Journal of urology, 2018-12
N. Engl. J. Med.,
Lancet Oncol., 2014 Feb 18
NEJM Evidence, 2022 Jun 1
Br J Cancer, 2014 Apr 15
Cancer, 2011-06-15
Eur J Cancer, 2017 Nov 28
N. Engl. J. Med., 2019 Sep 28
Lancet Oncol, 2021 Jan 18
J Clin Oncol, 2021 Apr 19
J Clin Oncol, 2003 Jul 01
JAMA, 2019 Apr 16
Head Neck, 2016 Mar 29
The Lancet. Oncology, 2017-05